Grifols (GRFS) Profit After Tax (2010 - 2020)
Grifols (GRFS) reported Profit After Tax of $224.7 million for Q1 2020, up 72.98% on a YoY basis from $129.9 million in Q2 2019, and down 54.53% quarter-over-quarter from $494.1 million in Q4 2019.
Grifols (GRFS) Profit After Tax (2010 - 2020) Analysis & Trends
Grifols has reported Profit After Tax for 10 years, with the latest figure at $224.7 million in Q1 2020.
- For the quarter ending Q1 2020, Profit After Tax rose 72.98% year-over-year to $224.7 million; the trailing twelve-month figure through Mar 2020 stood at $1.4 billion (up 25.73% YoY), and the FY2025 full-year result was $582.0 million, up 9415.33% from the prior year.
- Profit After Tax for Q1 2020 stood at $224.7 million, down from $494.1 million in the prior quarter.
- The five-year high for Profit After Tax was $532.4 million in Q4 2018, with the low at $24.5 million in Q4 2016.
- Historically, Profit After Tax has averaged $264.4 million across 5 years, with a median of $216.3 million in 2017.
- The largest YoY upside for Profit After Tax was 1973.58% in 2017 against a maximum downside of 56.45% in 2017.
- Grifols' Profit After Tax stood at $24.5 million in 2016, then soared by 1973.58% to $507.2 million in 2017, then rose by 4.99% to $532.4 million in 2018, then decreased by 7.2% to $494.1 million in 2019, then plunged by 54.53% to $224.7 million in 2020.
- The last three Profit After Tax figures came in at $224.7 million (Q1 2020), $494.1 million (Q4 2019), and $129.9 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 224.70 Mn |
| Dec 31, 2019 | 494.12 Mn |
| Mar 31, 2019 | 129.89 Mn |
| Dec 31, 2018 | 532.45 Mn |
| Jun 30, 2018 | 260.63 Mn |
| Mar 31, 2018 | 175.52 Mn |
| Dec 31, 2017 | 507.16 Mn |
| Jun 30, 2017 | 216.35 Mn |
| Mar 31, 2017 | 142.48 Mn |
| Dec 31, 2016 | 24.46 Mn |
| Sep 30, 2016 | 197.21 Mn |
| Jun 30, 2016 | 204.48 Mn |
| Mar 31, 2016 | 327.20 Mn |
| Dec 31, 2015 | 16.06 Mn |
| Sep 30, 2015 | 203.22 Mn |
| Jun 30, 2015 | 190.40 Mn |
| Mar 31, 2015 | 182.81 Mn |
| Sep 30, 2013 | 110.65 Mn |
| Jun 30, 2013 | 118.68 Mn |
| Mar 31, 2013 | 118.23 Mn |